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Transforming growth factor-b (TGF-b) plays a crucial role in the pathogenesis of skin ﬁbrotic diseases. Systemic
TGF-b inhibitors effectively inhibit ﬁbrosis in different animal models; however, systemic inhibition of TGF-b raises
important safety issues because of the pleiotropic physiological effects of this factor. In this study, we have
investigated whether topical application of P144 (a peptide inhibitor of TGF-b1) ameliorates skin ﬁbrosis in a well-
characterized model of human scleroderma. C3H mice received daily subcutaneous injections of bleomycin for 4
wk, and were treated daily with either a lipogel containing P144 or control vehicle. Topical application of P144
significantly reduced skin ﬁbrosis and soluble collagen content. Most importantly, in mice with established ﬁbro-
sis, topical treatment with P144 lipogel for 2 wk significantly decreased skin ﬁbrosis and soluble collagen content.
Immunohistochemical studies in P144-treated mice revealed a remarkable suppression of connective tissue growth
factor expression, ﬁbroblast SMAD2/3 phosphorylation, and a-smooth muscle actin positive myoﬁbroblast devel-
opment, whereas mast cell and mononuclear cell inﬁltration was not modiﬁed. These data suggest that topical
application of P144, a peptide inhibitor of TGF-b1, is a feasible strategy to treat pathological skin scarring and skin
ﬁbrotic diseases for which there is no specific therapy.
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Excessive accumulation of extracellular matrix (ECM) pro-
teins is the hallmark of fibrotic skin conditions such as
hypertrophic scarring, keloids, and localized or systemic
sclerosis (scleroderma). This process is dependent on the
activation of ECM synthesis in interstitial fibroblasts that
often develop into a-smooth muscle actin (a-SMA)-positive
myofibroblasts (Jimenez et al, 1996; Jelaska and Korn,
2000). One of the key molecular factors involved in both
processes is transforming growth factor-b (TGF-b), which is
consistently overexpressed in most fibrotic diseases and
displays a variety of profibrotic effects in fibroblasts
(Querfeld et al, 1999; Schiller et al, 2004). Activation of
TGF-b receptors leads to the activation of several kinase
signaling cascades, leading to the phosphorylation of
SMAD proteins as well as the activation of SMAD-inde-
pendent kinases that collectively activate ECM synthesis
and fibroblast growth and differentiation into myofibroblasts
(Shi and Massague, 2003; Daniels et al, 2004). Connective
tissue growth factor (CTGF) is a soluble mediator selectively
and rapidly induced in fibroblasts by the action of TGF-b
(Leask et al, 2004). CTGF has also been specifically de-
tected in skin fibrotic diseases (Igarashi et al, 1996), and in
animal models, it enhances and perpetuates the profibrotic
effects of TGF-b (Frazier et al, 1996).
Although most fibrotic diseases are usually initiated by
variable degrees of inflammation, anti-inflammatory thera-
pies are ineffective in targeting chronic fibrotic diseases that
represent an important group of disorders for which there is
no specific therapy. TGF-b appears as an attractive target
for the therapy of fibrotic diseases, and several anti-TGF-b
strategies have been successfully assayed in animal models
of fibrosis, including several murine models of scleroderma
(McCormick et al, 1999; Yamamoto et al, 1999b; Zhang
et al, 2003; Lakos et al, 2004). Systemic inhibition of TGF-b,
however, raises important safety concerns, because this
factor displays pleiotropic and potent effects in immuno-
modulation, inflammation, and tumor development
(Akhurst, 2002). Consistently, in TGF-b1-deficient mice,
skin scarring is reduced but they develop a severe wasting
syndrome accompanied by a generalized inflammatory re-
sponse and tissue necrosis, resulting in organ failure and
death (Bottinger et al, 1997). Therefore, local rather than
systemic TGF-b inhibition, or targeting of downstream fac-
tors involved in TGF-b profibrotic signaling represent alter-
native strategies for the development of anti-fibrotic
therapies (Daniels et al, 2004; Lakos et al, 2004). Local in-
hibition of TGF-b has previously been attempted by the di-
rect application of neutralizing antibodies on skin or corneal
open wounds, but the application of antibodies or large
peptides through the epidermal barrier appears to be an
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unpractical approach (Jester et al, 1997; Brahmatewari
et al, 2000).
We have previously reported that the peptide P144:
TSLDASIIWAMMQN, encompassing aminoacids 730–743
(accession number Q03167, SwissProt) from human TGF-
b1 type III receptor (b-glycan), was able to block the bio-
logical activity of TGF-b1 (Ezquerro et al, 2003). This peptide
is derived from the membrane-proximal ligand-binding do-
main of b-glycan (Esparza-Lopez et al, 2001), and similar to
soluble b-glycan (Lopez-Casillas et al, 1994), was able to
interfere with TGF-b1 binding to its cellular receptors on
Mv1Lu cells (Ezquerro et al, 2003). P144 prevented TGF-b1-
dependent inhibition of Mv1Lu cell proliferation and, in cul-
tured fibroblasts, it induced a concentration-dependent de-
crease on TGF-b1-dependent stimulation of a reporter gene
under the control of human a2(I) collagen promoter (Ezqu-
erro et al, 2003). Intraperitoneal administration of P144 also
showed potent in vivo anti-fibrotic activity in the liver of rats
receiving CCl4 (Ezquerro et al, 2003). Its small size and
highly lipophilic character may allow its local use by topical
application in skin fibrotic diseases, thereby reducing po-
tential systemic effects. To examine the potential anti-fi-
brotic effects of the topical application of this peptide
in vivo, we have tested P144 on a lipogel vehicle in an an-
imal model of skin sclerosis induced by bleomycin. This
model reproduces most of the features of human scler-
oderma such as skin-inflammatory cell infiltration, vascular
damage, mast cell activation, and prolonged skin fibrosis
(Yamamoto et al, 1999c). In this model, previous studies
have demonstrated that either the administration of anti-
TGF-b antibodies or genetic SMAD3 deficiency ameliorates
fibrosis development, strongly supporting a key role for
TGF-b (Yamamoto et al, 1999b; Lakos et al, 2004).
Results
In order to study the anti-fibrotic effect of P144 (a peptide
inhibitor of TGF-b1) on bleomycin-induced skin fibrosis, we
measured the changes induced in mice treated with
bleomycin for 4 wk with and without P144 administration.
It was found that bleomycin-treated mice showed a marked
increase of the collagen matrix of the dermis. The dermis
showed an increase of thickness that partially replaced the
subcutaneous fat when compared with phosphate-buffered
saline (PBS)-treated mice (Fig 1A). An increase in the col-
lagen matrix around the upper fascia of the paniculus car-
nosus muscle was also observed, and it was particularly
Figure 1
Histopathological evaluation of bleomycin-induced skin sclerosis in P144-treated mice. C3H mice received daily subcutaneous injections of
bleomycin (BLEO), and were treated topically with P144 lipogel emulsion (a peptide inhibitor of transforming growth factor-b1 (TGF-b1)) or vehicle
(VEHIC) for 4 wk, or for 2 wk after the 4 wk of bleomycin injections. Control mice were daily injected with phosphate-buffered saline (PBS). Skin
sections show the hematoxylin–eosin-stained dermis in A, and the hypodermal area over the paniculus carnosus muscle (m) stained with Masson’s
trichrome in B. Scale bars: 200 mm (A) and 50 mm (B). Data are representative of 10 mice per group.
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evident in Masson’s trichrome-stained sections of bleomy-
cin-treated mice skin (Fig 1B). An abundant inflammatory
infiltrate, mainly composed of mononuclear cells as well as
an increased number of mast cells, many of them showing
degranulation features, was also observed in bleomycin-
treated mice (data not shown). Mice treated with P144 anti-
TGF-b1 peptide showed a decrease of the dermal and
hypodermal collagen area compared with vehicle-treated
mice (Fig 1A, B). The thickness of the dermis was signif-
icantly decreased in P144-treated mice compared with ve-
hicle-treated mice, which showed a thickness similar to that
found in untreated mice (Fig 2). To confirm the histological
observation of decreased fibrosis in P144-treated mice, we
determined the pepsin-soluble collagen content of 4 mm
punch skin biopsies by a colorimetric Sircol-based assay.
This analysis showed a significant decrease of the soluble
collagen content in P144-treated mice (Fig 2). Changes in
the density of inflammatory cell infiltration, mast cell infil-
tration, or morphological changes of the epidermis were not
observed in the P144 or vehicle-treated mice compared
with those receiving only bleomycin injections (data not
shown).
We also evaluated the effect of treating mice with es-
tablished fibrosis after 4 wk of bleomycin injections, with
daily topical P144 treatment for 2 wk. After 6 wk, fibrosis
persisted in vehicle-treated mice, whereas mice treated
with P144 for 2 wk showed a significant decrease of dermal
thickness and collagen content (Figs 1 and 2).
To further characterize the cellular effects of neutralizing
TGF-b1 with P144, we analyzed its effect on the develop-
ment of a-SMA-positive myofibroblasts and fibroblast
SMAD2/3 phosphorylation induced by bleomycin. In con-
trol mice, a-SMA-positive myofibroblasts were rarely ob-
served, whereas an abundant number of these cells was
observed after 4 wk of bleomycin injections (Fig 3). P144-
treated mice showed a significant reduction in the number
of a-SMA-positive myofibroblasts compared with vehicle-
treated mice (Fig 3). We also observed an increase in the
number of dermal fibroblasts displaying phosphorylated
SMAD2/3 in a nuclear and cytoplasmic pattern in bleomy-
cin-injected mice, confirming previous observations in this
model (Takagawa et al, 2003). The number of phospho-
SMAD2/3-positive fibroblasts was also significantly de-
creased in P144-treated mice compared with vehicle-treat-
ed mice (Fig 4).
To determine whether CTGF expression, a well-known
downstream effector of TGF-b, is downregulated by
P144 peptide in bleomycin-treated mice, we performed
immunohistochemistry with L-20 polyclonal antibody. In our
study, this antibody specifically recognized a single 38 kD
protein, which was strongly induced by TGF-b1 treatment in
cultured fibroblasts (data not shown). CTGF expression was
strongly induced in fibroblasts and also in epidermis and
hair follicle epithelial cells of bleomycin-treated mice (Fig 5).
P144 treatment clearly decreased CTGF expression in the
epidermis and hair follicles, compared with vehicle-treated
mice, whereas fibroblast CTGF was still detectable after
P144 therapy (Fig 5).
Figure 2
Effect of P144 lipogel emulsion administration on dermal thickness
and soluble collagen content in bleomycin-treated mice. Dermal
thickness was measured on digitalized images from hematoxylin–eo-
sin-stained sections. Soluble collagen content was determined by the
colorimetric Sircol method in pepsin-digested homogenates of skin
biopsies. Three groups of mice were treated as follows: (i) phosphate-
buffered saline (PBS) (open bar) or bleomycin (filled bar) for 4 wk, (ii)
bleomycin plus P144 lipogel emulsion (open bar) or bleomycin plus
vehicle: lipogel emulsion without P144 (filled bar) for 4 wk, and (iii)
bleomycin only for 4 wk, treatment with P144 lipogel emulsion (open
bar) or vehicle (filled bar) during 2 wk. Data represent mean  SD of 10
mice per group, and the values of PBS-treated mice are set to 100%.
po0.05.
Figure3
Immunofluorescent detection of myofibroblasts in skin sections of
bleomycin-injected and P144 lipogel emulsion-treated mice. Sec-
tions were labeled with anti-a-smooth muscle actin (SMA)–fluorescein
isothiocyanate (FITC) and examined under a fluorescence microscope.
Scale bar: 40 mm. The mean  SD number of SMAþcells per field is
shown. Data are representative of 10 mice per group. po0.05.
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Discussion
The effectiveness of systemic strategies targeting TGF-b
during the development of experimental skin fibrosis has
been previously demonstrated. The natural human latency-
associated peptide, and neutralizing anti-TGF-b1 antibod-
ies have shown to prevent the development of skin fibrotic
lesions effectively in different experimental models (McCor-
mick et al, 1999; Yamamoto et al, 1999b; Zhang et al, 2003).
These molecules are large enough to prevent its diffusion
through the epidermal barrier. We have tested the feasibility
of using a smaller lipophilic peptide, based on a conserved
region of human type III TGF-b1 receptor, as a topical ther-
apy for skin fibrosis.
Our data consistently show that daily application of this
peptide for 4 wk in parallel to fibrogenic bleomycin subcu-
taneous injections prevents fibrosis. Furthermore, and more
importantly, regarding human skin fibrotic diseases, estab-
lished fibrosis was also significantly reduced following top-
ical application of peptide P144 for 2 wk. Improvement of
established skin fibrosis in this model by post-onset therapy
has been previously demonstrated with systemic interferon-
g, or superoxide dismutase therapy but not with systemic
TGF-b inhibitors (Yamamoto et al, 1999a, b, 2000). We de-
cided to test topical application of P144 because it was
thought that in the case of bleomycin-induced scleroderma,
this would be more efficacious than systemic administration
of this peptide inhibitor. Also, in the event of P144 being
toxic, topical application might reduce toxic side-effects
that might be encountered following systemic administra-
tion of P144.
In previous studies in the bleomycin-induced scleroder-
ma model, treatment with systemic anti-TGF-b antibodies
reduced fibrosis in parallel to a reduction in mast cell and
inflammatory cell infiltration (Yamamoto et al, 1999b). The
relevance of mast cells in skin fibrosis models is uncertain,
because previous studies in mast cell-deficient mice have
shown their dispensable contribution to fibrosis develop-
ment (Everett et al, 1995; Yamamoto et al, 2001). Inflam-
matory cell infiltration plays an important role in the early
stages of fibrosis development but its role is less clear at
Figure 4
Immunohistochemical detection of phospho-SMAD2/3 in skin sec-
tions of bleomycin-injected and P144 lipogel emulsion-treated
mice. Skin sections were labeled with a specific anti-phospho-SMAD2/
3 antibody and developed with diaminobenzidine substrate (brown).
Labeled fibroblasts are marked by arrows. Sections are hematoxylin
counterstained. Scale bar: 50 mm. The mean  SD number of phospho-
SMAD2/3-positive fibroblasts per field is shown. Data are represent-
ative of five mice per group. po0.05.
Figure5
Immunohistochemical detection of connective tissue growth fac-
tor (CTGF) in skin sections of bleomycin-injected and P144 lipogel
emulsion-treated mice. Skin sections were labeled with a specific
anti-CTGF antibody and developed with diaminobenzidine substrate
(brown). Sections are hematoxylin counterstained. Images are repre-
sentative of 10 mice per group. Scale bar: 50 mm.
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later stages, where it can either resolve or persist inde-
pendent of the progression of fibrosis. Indeed, at later
stages, fibrosis usually progresses in the absence of sig-
nificant inflammatory cell infiltration. Our data and similar
data using latency-associated peptide in a model of graft
versus host scleroderma, or in SMAD3-deficient mice
challenged with bleomycin, suggest that fibrosis can be
decreased by antagonizing TGF-b independent of inflam-
matory cell infiltration (Zhang et al, 2003; Lakos et al, 2004).
The mainstay of therapy for dermatological diseases re-
mains topical therapy because it can readily target lesional
skin decreasing systemic effects of the active principles;
however, delivery of large peptides is limited by their size
and physicochemical properties. We took advantage of the
small size of P144 peptide and its lipophilic properties,
which allowed for its application as a lipogel. Although der-
mal absorption of the peptide is yet to be demonstrated, our
data suggest that topical application of this peptide effi-
ciently interferes with TGF-b action on dermal fibroblasts as
critical players of TGF-b profibrotic responses. Alternatively,
its local accumulation in the epidermis could have poten-
tially contributed to its anti-fibrotic effects. In this regard,
cross-talk between the epidermis and the dermis during fi-
brosis development may occur, as profibrotic factors such
as TGF-b and monocyte chemoattractant protein 1 (MCP-1)
have been detected in the epidermal layer of fibrotic skin
(Galindo et al, 2001; Flanders et al, 2002). Indeed, keratin-
ocyte overexpression of TGF-b1 in transgenic mice induces
dermal fibrosis (Ito et al, 2001; Yang et al, 2001; Chan et al,
2002). Interestingly, our study points to CTGF induction in
skin keratinocytes of bleomycin-treated mice, which
was reduced by topical anti-TGF-b therapy to a higher ex-
tent than in dermal fibroblasts. Although the role of epider-
mal CTGF has not been established in fibrosis, previous
studies demonstrate that it is expressed by normal keratin-
ocytes in vivo (Quan et al, 2002). Also, its downregulation by
ultraviolet (UV) radiation has been linked to the reduction in
procollagen synthesis induced by UV radiation (Quan et al,
2002).
The demonstration of the effectiveness of topical appli-
cation of a peptide inhibitor of TGF-b1 provides a potentially
fruitful strategy for the therapy of pathological scarring and
skin fibrotic diseases. Experiments are being carried out to
determine as to what extent P144 might be systemically
absorbed through the skin. These experiments, together
with a study of the potential toxicity of P144, will determine
whether this peptide is suitable for human therapy.
Materials and Methods
Female C3H mice aged 6 wk were obtained from Harlan SL
(Barcelona, Spain). Bleomycin (Sigma, Madrid, Spain) was dis-
solved in PBS at 100 mg per mL. Using a 27-gauge needle, 100 mL
of filter-sterilized bleomycin or PBS was injected subcutaneously
into the shaved back skin. Injections in the same site were ad-
ministered daily for 4 wk. Mice were euthanized by CO2 asphyx-
iation 24 h after the final injection. The back skin was removed and
processed for histological examination, and 4 mm diameter punch
biopsies were frozen for protein analysis. The study was approved
by the ethical committee of Universidad Complutense de Madrid,
Spain.
P144 peptide was originally developed and synthesized in our
laboratory using the solid-phase method (Merrifield, 1963) and the
Fmoc alternative (Atherton et al, 1989) as described previously
(Borra´s-Cuesta et al, 1991). P144 used in this study was purchased
from Sigma-Genosys Ltd, Cambridge, UK. Peptide was at least
90% pure as per high-performance liquid chromatography and
mass spectrometry. Two lipogel emulsions were prepared: a lipogel
emulsion containing P144 and a control vehicle emulsion without
P144. The vehicle lipogel emulsion was prepared by mixing the
following components: 10 g dimethicone, 40 g liquid paraffin, 0.1 g
chlorocresol, 0.5 g cetrimide, and 5 g ketostearic alcohol. This
mixture was warmed to 701C and emulsified with 44.4 g of distilled
water (also at 701C). The P144 lipogel emulsion was prepared in an
identical manner, but the 44.4 g of water were replaced by a mix-
ture of 44.28 of water plus 0.010 g of P144 previously dissolved in
100 mL of dimethyl sulfoxide.
Two groups of mice were given a daily application of either 100
mL of the P144 peptide lipogel preparation or control vehicle onto
the shaved skin area during the 4 wk of bleomycin injections. Ad-
ditional groups of mice received bleomycin injections for 4 wk, and
thereafter, vehicle or P144 peptide were applied daily for 2 wk
before sacrifice.
Pepsin-soluble collagen is an extractable fraction that repre-
sents recently synthesized collagen in tissues. It was quantified in 4
mm diameter punch biopsies of the back skin and adjusted by
weight. Briefly, after skin homogenization, pepsin-soluble colla-
gens were extracted overnight with 5 mg per mL pepsin in 0.5 mol
per liter acetic acid. The soluble collagen content was determined
using the Sircol Collagen Assay kit (Biocolor, Newtownabbey,
Northern Ireland), according to the manufacturer’s instructions.
Additional skin samples were snap-frozen in liquid nitrogen and
embedded in optimal cutting temperature (OCT) medium for his-
tological and immunohistochemical studies. Skin sections were
stained with hematoxylin and eosin, Masson’s trichrome, and to-
luidine blue for metachromatic staining of mast cells. Myofibro-
blasts were detected in skin sections by immunofluorescent
labeling with an fluorescein isothiocyanate-labeled anti-a-SMA
mAb (Sigma), and directly photographed under a Zeiss Axioplan-2
fluorescence microscope (Jena, Germany). For immunohistochem-
ical detection of CTGF and phosphorylated-SMAD2/3, we used
polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, Cal-
ifornia) and a biotin peroxidase-based method (ABC, Vector Lab-
oratories, Burlingame, California). Slides were developed with
diaminobenzidine chromogen and counterstained in Gill’s hem-
atoxylin.
For histomorphometrical analyses, three random fields of each
skin biopsy were photographed and digitalized using a Spot RT
CCD camera and Spot 4.0.4 software (Diagnostic Instruments,
Sterling Heights, Michigan). The thickness of the dermis was
measured, and the number of myofibroblasts, phosphorylated-
SMAD2/3 positive fibroblasts, or mast cells per 400  field were
also counted on digitalized images.
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